Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

ABSTRACT:

Background

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer.

Methods

In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials.

Results

After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane-ovarian s

SUBMITTER: Pagani O 

PROVIDER: S-EPMC4175521 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature